English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In recent years, neutrophil gelatinase-associated lipocalin (NGAL) emerged as a potential marker for early detection of kidney damage (1, 2) . However, ELISA techniques, which are particularly diffi cult to use in routine clinical practice on a 24-h/7-day basis, were used in the majority of these investigations (3, 4) . Commercial kits for the determination of NGAL that could be applied to routine chemistry analy zers were introduced very recently (5) . The automated non-competitive two-site sandwich immunoassay supplied by Abbott Laboratories (Abbott Park, IL, USA) which allows the determination of urinary NGAL with the Architect platform was shown to give more precise results than the Triage (BiositeIverness Medical, Waltham, MA, USA) point-of-care immunoassay for NGAL in whole blood or plasma. A new particle enhanced turbidimetric immunoassay (PETIA) supplied by Bioporto Diagnostics A/S (Gentofte, Denmark) for the determination of NGAL in urine or EDTA-plasma can be adapted to a variety of clinical chemistry analyzers, thereby fulfi lling the 24/7 prerequisite necessary for early detection of kidney damage. In our laboratory, this PETIA assay (prod. no.: ST001RA, Bioporto) was adapted to a Modular P analyzer (Roche GmbH, Mannheim, Germany) according to the manufacturer ’ s instructions. During a two-month evaluation period using one lot of reagents and four calibration cycles, this PETIA assay proved to be reproducible when using the NGAL control kit of Bioporto (prod. no.: ST003RA) as shown by the results: control low: mean ± SD = 196 ± 6.7 μ g/L, n = 36, CV = 3.4 % ; control high: mean ± SD = 492 ± 13.3 μ g/L, n = 36, CV = 2.7 % . These CV results are in accordance with the CV numbers stated by the supplier in their kit insert. Therefore,

Neutrophil gelatinase-associated lipocalin: comparison of the use of EDTA and heparin plasma